Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Rapid Diagnostic Classification and Risk Stratification in AML Using Whole Genome Sequencing

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWayne M. JepsenJKJonathan J. KeatsSBSara A. Byron

Discussion

Loading...

Member takes

Overview

Shows improved classification and risk assessment using rapid whole genome sequencing in AML patients, indicating faster treatment decisions.

Key Points

  • To develop a rapid whole genome sequencing (WGS) approach for diagnosing and stratifying risk in acute myelogenous leukemia (AML).
  • Developed ALTseq, a rapid whole genome sequencing assay for AML.
  • Streamlined laboratory workflows and enhanced bioinformatic pipelines.
  • Assessed clinical utility by analyzing variant detection for key AML-related aberrations.
  • Achieved a mean turnaround time of 33 hours for test results.
  • Detected genomic alterations with high sensitivity (up to 100%).
  • Influenced treatment decisions based on identified genetic fusions and rearrangements.

Cite This Study

Jepsen et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a26f7https://doi.org/10.1158/1538-7445.am2026-2495
View Full Paper
Ask AI
Bookmark
Share